PBRT successfully spared cardiac and lung tissues while delivering a homogenous dose to the target tissue.
A question often asked by patients recommended for radiation treatment is whether outcomes might be improved with proton-beam radiation therapy (PBRT) versus conventional radiation therapy. To date, PBRT is often used for pediatric tumors, central nervous system tumors, and genitourinary malignancies. However, data supporting its use for breast cancer is lacking.
Now, investigators have conducted a prospective phase II study of the use of PBRT in a cohort of 69 women (median age, 45 years) with nonmetastatic breast cancer requiring postoperative regional nodal irradiation. Patients were eligible if they were not ideal candidates for conventional radiation due to breast reconstruction that would prevent target coverage, or if they were expect…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)